Pioneering liver disease treatments
Galmed Pharmaceuticals (galmedpharma.com) earns a Brand Analyzer score of 54 out of 100, placing it in the Early Stage tier among Healthcare brands. Among 2305 Healthcare brands analyzed, Galmed Pharmaceuticals ranks in the 5th percentile (category average 68, leader 95). The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark. Dimension scores: Name Quality 77/100, Digital Presence 71/100, Visual Identity 45/100, Messaging Clarity 100/100, Trust Foundation 59/100, AI Discoverability 28/100, Brand Authority 9/100.
Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company founded in 2000 and headquartered in Tel Aviv, Israel. The company focuses on developing innovative therapies for fibrotic liver diseases, including non-alcoholic steatohepatitis (NASH). Its lead candidate, Aramchol, is a novel oral small molecule designed to target fibrosis resolution in liver diseases. Galmed serves healthcare professionals, patients, biotech investors, and pharmaceutical partners seeking advances in NASH treatment.
| Brand Name | Galmed Pharmaceuticals |
|---|---|
| Domain | galmedpharma.com |
| Industry | Healthcare |
| Founded | 2000 |
| Headquarters | Tel Aviv |
| Main Competitors | Madrigal Pharmaceuticals, Intercept Pharmaceuticals, Gilead Sciences (81/100), Novo Nordisk, Akero Therapeutics, 89bio |
Moz Domain Authority 34/100 vs category average 29 / leader 95 - a strong backlink profile, so AI systems frequently encounter mentions of the brand.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "Galmed Pharmaceuticals is dedicated to developing innovative therapies for fibrotic liver diseases including NASH." (No meta description) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: No structured data or Open Graph tags detected. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: No robots.txt found (default: all bots allowed, but explicit file preferred) - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Social footprint: verified profiles on Facebook, Instagram; no detected presence on X (Twitter), LinkedIn, YouTube, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Galmed Pharmaceuticals scores 27/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Galmed Pharmaceuticals has a weak AI-visibility profile at 27/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (45/100) and its weakest is visibility (21/100). It benefits from a Wikidata knowledge-graph entry and open access for AI crawlers (GPTBot, ClaudeBot, etc.). The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, a low Moz Domain Authority of 34/100 and thin schema.org structured data.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Galmed Pharmaceuticals's main competitors include Madrigal Pharmaceuticals, Intercept Pharmaceuticals, Gilead Sciences (81/100), Novo Nordisk, Akero Therapeutics. These companies compete in the Healthcare space for similar customers, offering comparable products or services.
Sources: Galmed Pharmaceuticals official site
Galmed Pharmaceuticals and Gilead Sciences are competitors in Healthcare. Brand Analyzer scores Galmed Pharmaceuticals at 54/100 and Gilead Sciences at 81/100. They target overlapping audiences; the right choice depends on your specific needs and priorities.
Sources: Galmed Pharmaceuticals official site
Galmed Pharmaceuticals' primary product candidate is Aramchol, a novel oral small molecule designed to target fibrosis resolution in liver diseases, with a specific focus on NASH (non-alcoholic steatohepatitis). Aramchol is described as having a favorable safety profile and is intended to address unmet needs in NASH treatment. The company's broader platform is an oral small molecule approach to treating fibrotic liver diseases.
Sources: Galmed Pharmaceuticals official site
Popular alternatives to Galmed Pharmaceuticals include Madrigal Pharmaceuticals, Intercept Pharmaceuticals, Gilead Sciences (81/100), Novo Nordisk, Akero Therapeutics. Each is an established option in the Healthcare space; the best fit depends on your specific needs, budget, and required features.
Sources: Galmed Pharmaceuticals official site
Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company headquartered in Tel Aviv, Israel, founded in 2000. It positions itself as a leader in liver fibrosis and NASH (non-alcoholic steatohepatitis) therapeutics. The company operates within the healthcare sector, focusing on the development of innovative treatments for fibrotic liver diseases through a novel oral small molecule platform.
Sources: Galmed Pharmaceuticals official site
Galmed Pharmaceuticals has limited AI-search visibility, scoring 27/100 on Brand Analyzer's AI visibility composite (visibility 21, trust 22, recommendation 45). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Galmed Pharmaceuticals official site
Galmed Pharmaceuticals was founded in 2000. Galmed Pharmaceuticals operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
Galmed Pharmaceuticals is headquartered in Tel Aviv. Galmed Pharmaceuticals operates in the Healthcare category.
Sources: Wikidata
Galmed Pharmaceuticals develops innovative therapies targeting fibrotic liver diseases, including NASH. The company focuses on a novel, oral small molecule platform designed to resolve fibrosis in liver diseases. Its lead drug candidate, Aramchol, is being developed to address unmet medical needs in NASH treatment. The company aims to bring forward therapies with favorable safety profiles for patients suffering from serious liver conditions.
Sources: Galmed Pharmaceuticals official site
Galmed Pharmaceuticals scores 45/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: Galmed Pharmaceuticals official site
Galmed Pharmaceuticals is known for its clinical-stage development of Aramchol, a novel oral small molecule candidate targeting fibrosis resolution in liver diseases, particularly NASH (non-alcoholic steatohepatitis). The company is recognized for its focus on an underserved therapeutic area - fibrotic liver disease - and for its oral small molecule platform approach aimed at addressing significant unmet clinical needs in NASH treatment.
Sources: Galmed Pharmaceuticals official site
Galmed Pharmaceuticals can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Galmed Pharmaceuticals official site
Galmed Pharmaceuticals' work is relevant to several distinct groups. Healthcare professionals treating patients with NASH and liver fibrosis are a primary audience, as are patients themselves who suffer from these conditions. Investors in the biotechnology sector and potential pharmaceutical partners seeking to collaborate on or license liver disease therapeutics also represent key stakeholders and audiences for Galmed Pharmaceuticals.
Sources: Galmed Pharmaceuticals official site
Ranked closest to Galmed Pharmaceuticals: New Medical Servis (54/100), Environmental Modifications (54/100), Grace Blood (54/100), Healthy Chocolate® (54/100).
A step up - brands to learn from: Werskincare (56/100), Virtue TCM 醫道閣 (56/100).
Category leader: Dassault Systèmes (95/100).